Effect of quercetin on paraoxonase 1 activity - studies in cultured cells, mice and humans

Journal of Physiology and Pharmacology

Volumn 61, Issue 1, 2010, Pages 99-105

  Boesch Saadatmandi, C ^a   Egert, S ^a   Schrader, C ^a   Coumoul, X ^b   Barouki, R ^b   Muller, M J ^a   Wolffram, S ^a   Rimbach, G ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b INSERM   (France)

Author keywords

Atherosclerosis; Flavonoidmetabolism; Isorhamnetin; Paraoxonase 1; Quercetin

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; MESSENGER RNA; QUERCETIN; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOOD INTAKE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; MALE; MOUSE; NONHUMAN; REPORTER GENE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SPECIES DIFFERENCE; TUMOR CELL CULTURE; YOUNG ADULT;

ADULT; ANIMALS; ARYLDIALKYLPHOSPHATASE; DOUBLE-BLIND METHOD; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; QUERCETIN; SPECIES SPECIFICITY; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77954304386     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
2. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo- Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
4. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275: 3957-3962.
5. Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 2008; 59(Suppl 9): 155-167.
6. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287.
7. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-490.
8. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779.
9. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 371-392.
10. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76
11. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17: 2935-2939.
12. Ferre N, Camps J, Fernandez-Ballart J, et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003; 49: 1491-1497.
13. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69: 541-550.
14. Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol 2002; 22: 1248-1250.
15. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a doubleblinded, placebo-controlled cross-over study. Br J Nutr 2009: 102: 1065-1074.
16. Boesch-Saadatmandi C, Wolffram S, Minihane AM, Rimbach G. Effect of apoE genotype and dietary quercetin on blood lipids and TNF-alpha levels in apoE3 and apoE4 targeted gene replacement mice. Br J Nutr 2009; 101: 1440-1443.
17. Huebbe P, Wagner AE, Boesch-Saadatmandi C, Sellmer F, Wolffram S, Rimbach G. Effect of dietary quercetin on brain quercetin levels and the expression of antioxidant and Alzheimer's disease relevant genes in mice. Pharmacol Res 2009; Aug 29, epub ahead of print.
18. Hayek T, Fuhrman B, Vaya J, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997; 17: 2744-2752.
19. de Whalley CV, Rankin SM, Hoult JR, Jessup W, Leake DS. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem Pharmacol 1990; 39: 1743-1750.
20. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a metaanalysis of randomized controlled trials. Am J Clin Nutr 2008; 88: 38-50.
21. Gouedard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 2004; 24: 5209-5222.
22. Egert S, Wolffram S, Bosy-Westphal A, et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 2008; 138: 1615-1621.
23. Bieger J, Cermak R, Blank R, et al. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 2008; 138: 1417-1420.
24. Charlton-Menys V, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clin Chem 2006; 52: 453-457.
25. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.
26. Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003; 63: 945-956.
27. Gouedard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol 2004; 24: 2378-2383.
28. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002; 277: 4301-4308.
29. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. 104 Review of 97 bioavailability studies. Am J Clin Nutr 2005; 81: 230S-242S.
30. Weldin J, Jack R, Dugaw K, Kapur RP. Quercetin, an overthe- counter supplement, causes neuroblastoma-like elevation of plasma homovanillic acid. Pediatr Dev Pathol 2003; 6: 547-551.
31. Osaki F, Ikeda Y, Suehiro T, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 2004; 176: 279-287.
32. Tsakiris S, Karikas GA, Parthimos T, Tsakiris T, Bakogiannis C, Schulpis KH. Alpha-tocopherol supplementation prevents the exercise-induced reduction of serum paraoxonase 1/arylesterase activities in healthyindividuals. Eur J Clin Nutr 2009; 63: 215-221.
33. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004; 23: 423-433.
34. Aviram M, Dornfeld L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000; 71: 1062-1076.